Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19

INTERVENTION: Intervention 1: Intervention group: Interferon Beta 1a nasal spray 1 puff in each nostril every 6 hours, for 14 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona‐virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona‐virus. CONDITION: COVID‐19. ; Covid‐19 U07.1 PRIMARY OUTCOME: Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire. Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer. Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse‐oxymetery device. SECONDARY OUTCOME: Lab. tests changes. Timepoint: Daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: Blood sample, laboratory analysis. Mortality. Timepoint: Day 14 from the initiation. Method of measurement: Clinical assessment. Side effects. Timepoint: Daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: Physical examination. INCLUSION CRITERIA: Age: equal or more than 18 years; The patient have written consciously and freely consent to participate in the study; The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID‐19. Confirmed diagnosis of COVID‐19, with either lung CT‐Scan result, which is typical for COVID‐19 pulmonary involvement,or RT‐PCR confirmation. Less than 7 days have passed since the onset of symptoms.